DOR BioPharma to Present at Upcoming Southern California Investment Association Conference.

MIAMI -- DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company"), announced today that Geoff Green, President and Acting Chief Executive Officer, will be giving a presentation on DOR at the Southern California Investment Association (SCIA) Conference, in Newport Beach, CA, this coming Saturday.

Mr. Green will provide an overview of the Company's BioDefense and Biotherapeutic Divisions, including its strategic plans for DOR's ricin and botulinum toxin vaccines, as well as DOR's lead therapeutic product, orBec(R), which is currently completing a pivotal Phase III clinical trial for the indication of treatment of intestinal Graft-versus-Host Disease. Mr. Green's presentation will take place at approximately 9:00 AM, Saturday, August 7, 2004 at the Orange County Airport Hilton, 18800 MacArthur Boulevard, Irvine (Newport Beach), CA 92612-2004.

Southern California Investment Association, Inc. is a comprehensive organization developed to facilitate stock support and capital formation for select companies. SCIA is composed of an expanding national alliance of more than one hundred and fifty NASD member firms, investment and merchant bankers, investment advisors, analysts, financial service managers, venture capitalists, investor relations, industry consultants, securities attorneys, media and qualified investors.

SCIA's goal is to assist their member network and to build exposure and support for small to medium size listed and emerging-growth companies by providing a bimonthly forum. SCIA's forum showcases cutting-edge national and international presenting companies.

For further details about attending the presentation, please visit sciaonline.org or call [phone].

About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company developing biodefense vaccines and therapeutics for unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered vaccines designed to induce protective immunity against the harmful effects of ricin toxin and botulinum toxin. The Centers for Disease Control (CDC) has identified these toxins as potential bioterror threats and DOR intends to develop these countermeasures in part by taking advantage of the recently enacted legislation Project Bioshield Act 2004, a $5.6 billion biological, chemical, radiological and nuclear anti-terror law designed to offer incentives and a market for bioterror countermeasures developed by industry. DOR's lead product, orBec(R) (oral beclomethasone dipropionate), has recently completed enrollment in a multicenter, pivotal phase III clinical trial for the treatment of acute intestinal graft-vs-host disease, a form of serious and life-threatening gastrointestinal inflammation. OrBec(R) is a topically-active corticosteroid that has a potent local effect on inflamed mucosal tissue. For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma's current expectations about its future results, performance, prospects and opportunities. Where possible, DOR BioPharma has tried to identify these forward-looking statements by using words such as "anticipates," "believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR BioPharma cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that, product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully enter into profitable biodefense contracts with the U.S. Government and other countries, under the Project Bioshield Act of 2004, or otherwise, meet anticipated projections or, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR BioPharma's most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.